MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorectal cancer

BACKGROUND: MODUL is an adaptable, signal-seeking trial designed to test novel agents in predefined patient subgroups in first-line metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with measurable, unresectable, previously untreated mCRC received induction with ≤8 cycles of FOLFOX...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, J., Grothey, A., Arnold, D., de Gramont, A., Ducreux, M., O’Dwyer, P., Tahiri, A., Gilberg, F., Irahara, N., Schmoll, H.-J., Van Cutsem, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588902/
https://www.ncbi.nlm.nih.gov/pubmed/36029653
http://dx.doi.org/10.1016/j.esmoop.2022.100559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588902/
https://www.ncbi.nlm.nih.gov/pubmed/36029653
http://dx.doi.org/10.1016/j.esmoop.2022.100559

Ejemplares similares